DKSH invests in pharmaceutical laboratory facilities

(29.10.2010, Pharma-Zeitung.de) DKSH, the leading Market Expansion Services provider with a focus on Asia, has invested in two pharmaceutical laboratories to deepen the company’s application expertise. The new facilities recently opened their doors in Japan and the Philippines.

Zurich, October 29, 2010 – DKSH’s Business Unit Performance Materials, a leading distributor of specialty chemicals and pharmaceutical ingredients, has invested in new pharmaceutical laboratories to deepen the company’s application expertise, develop innovative business ideas, and formulate solutions that create even better opportunities for its suppliers and customers.

In Isogo, Japan, DKSH has invested in a high containment laboratory to support the registration process of APIs. The brand new, state-of-the-art infrastructure will ensure the company’s strong pipeline of oncology products and other APIs. Known as a first-class service provider, DKSH will provide its business partners drug master filing and method validation of analytics.

The second pharmaceutical innovation center opened its doors in Laguna, Philippines, earlier this year to offer technical pilot trials for tablet coating applications as well as prototype formulation of taste-masked children’s antibiotics (in suspension/syrup) using DKSH’s specialty excipients.

As Dr. Hansjoerg Jakubetz, Vice President Pharmaceutical Industry, puts it: “Since the population is getting older cancer is one of the most important problems we are facing now and in the future. With our investment we secure the pipeline of cancer drugs into the market. In addition, we offer now prototype formulations in South East Asia which are created in our own new laboratory in the Philippines.”


Über DKSH

About DKSH

DKSH is the leading Market Expansion Services Group with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. With 560 business locations in 35 countries – 20 of them in Europe and the Americas – and 22,000 specialized staff it is one of the top 20 Swiss companies ranked by sales and employees. In 2009, DKSH generated annual gross revenues of CHF 8,600 million.

DKSH’s Business Unit Performance Materials is a leading global provider of Market Expansion Services for performance materials. The Business Unit sources, develops, markets, and distributes a wide range of specialty chemicals and ingredients to business partners in the food and beverage, personal care and cosmetics, pharmaceutical, and specialty chemical industries.

With 57 business locations in 24 countries and 1,200 specialized staff, Business Unit Performance Materials generated annual gross revenues of CHF 703 million in 2009.

Weitere Informationen anfordern

Kontaktieren Sie den Autor um weitere Informationen zu erhalten. Füllen Sie das folgende Formular aus und erhalten Sie kostenfrei und unverbindlich weitere Informationen vom Anbieter.

Firma
Anfrage
Name
E-Mail
Telefon

Weitere Pressemitteilungen von DKSH

28.01.2013 DKSH und SGS verlängern Prüfungs- und Zertifizierungs-Partnerschaft für weitere drei Jahre
26.10.2010 Die Sparte Healthcare von DKSH erlangt 17 internationale Qualitätszertifizierungen von der SGS (Société Générale De Surveillance) für ihre Vertriebszentren in Asien

Newsletter abonnieren


Ansprechpartner

For further information please contact:
DKSH
Seraina Peter
Communications Manager
Business Unit Performance Materials
seraina.peter@dksh.com, www.dksh.com/performancematerials




Partner
Medizinische Übersetzungen
Zerfallszeittester / Disintegration Tester DISI

Ihre Pressemitteilung hier?

Nutzen Sie Pharma-Zeitung.de für effektive Pressearbeit und Neukundengewinnung.

» Pressemitteilung veröffentlichen

 




AKTUELLE PHARMA SEMINARE